Moderna slips as Goldman Sachs downgrades on revenue outlook
Moderna’s stock is falling. Goldman Sachs says it’s no longer a buy.
Shares of vaccine maker Moderna fell Wednesday as Goldman Sachs lowered its rating after the biotech’s second cut to product revenue guidance in six months.
Moderna downgraded to Neutral from Buy at Goldman Sachs
Goldman Sachs downgraded Moderna (MRNA) to Neutral from Buy with a price target of $51, down from $99. The recent product revenue guidance
Yen on MSN10d
In US, teleworkers don’t want to turn back after pandemic
Five years after the Covid-19 pandemic sent workers scrambling for home ... with few exceptions such as Goldman Sachs and Tesla, which quickly mandated full-time office attendance. Now, several major companies are abandoning the compromise approach.
America's economic and market dominance is here to stay in 2025
A risk-taking culture, geographic advantages, and strong consumer spending continue to drive US economic growth way ahead of its peers.
Goldman Sachs Expects $1 Trillion Of Stock Buybacks In 2025
U.S. investment bank Goldman Sachs (GS) is forecasting $1 trillion U.S. of stock buybacks in 2025, the most in the past five years. Goldman Sachs analyst Scott Rubner says equity markets could get a boost in coming months following a corporate share